CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Hiring the Right CRO to Improve Clinical Trial Outcomes

Hiring the Right CRO to Improve...

 Altasciences Receives Accreditation From College Of American Pathologists

Altasciences Receives Accreditation...

Life Science Marketing: Content Distribution for Businesses

Life Science Marketing: Content...

Protypia, Inc.'S Acquisition By Inotiv, Inc. Broadens The Company's Protein/Peptide Bioanalytical Capabilities

Protypia, Inc.'S Acquisition By...

Making the Most of Contract Research Organization Relationships

Making the Most of Contract Research...

How Cloudbased Lims Helps Cros

How Cloudbased Lims Helps Cros

MMS Holdings Announces New Pro-Bono Support Program

MMS Holdings Announces New Pro-Bono...

Inotiv Secures MilliporeSigmas BioReliance Genetic Toxicology Assets

Inotiv Secures MilliporeSigmas...

Hiring the Right CRO to Improve Clinical Trial Outcomes

Hiring the Right CRO to Improve...

 Altasciences Receives Accreditation From College Of American Pathologists

Altasciences Receives Accreditation...

Life Science Marketing: Content Distribution for Businesses

Life Science Marketing: Content...

Protypia, Inc.'S Acquisition By Inotiv, Inc. Broadens The Company's Protein/Peptide Bioanalytical Capabilities

Protypia, Inc.'S Acquisition By...

Making the Most of Contract Research Organization Relationships

Making the Most of Contract Research...

How Cloudbased Lims Helps Cros

How Cloudbased Lims Helps Cros

MMS Holdings Announces New Pro-Bono Support Program

MMS Holdings Announces New Pro-Bono...

Inotiv Secures MilliporeSigmas BioReliance Genetic Toxicology Assets

Inotiv Secures MilliporeSigmas...

How an AI Boost Benefits in Clinical Trials

Life Sciences Review | Thursday, May 20, 2021
Tweet

Leveraging AI can expedite and enhance patient care at screening, diagnosis, and treatment, including better patient journey management.


FREMONT, CA: AI-based capabilities, including data integration and interpretation, pattern recognition, and evolutionary modeling, are vital to gather, normalize, analyze and harness the increasing masses of data that fuel innovative therapy development. Indeed, AI and modern analytics were viewed as the digital technology with the most potential to enhance clinical R&D productivity in the digital disruption in the biopharma sector. AI has several potential applications in clinical trials. AI technologies make possible innovations vital for transforming clinical trials, like seamlessly coupling clinical trials, developing new patient-centered endpoints, and collecting and analyzing data.


The fact that there are several drugs in clinical development, comprising some targeting the same or similar indications, also releases new levels of competition both for patients to participate in clinical research and commercialization. These development programs follow the long-established method of selecting and targeting cells with higher proliferation activity connectivity with the disease. Manufacturers have focused clinical research on targeting the root cause of disease to offer an optimal and potentially curative advantage. This shift has also introduced the requirement for more advanced protocols in patient screening and the execution of clinical research.


Firms are leveraging options, including innovative neural networks and Bayesian algorithm-powered software systems to mine datasets of patient information to find enrollment candidates. Many are also leveraging AI to deploy predictive models to enhance the statistical significance of data collected from more targeted candidates and help mitigate trial costs.  AI tools can enhance the potential to assess which patient candidates might respond better to drug treatment and predict their trial dropout rates.


Latest AI tools also enable drug manufacturers to better assess issues related to drug administration and optimal dosing regimens. Customized algorithms can decide the impact of various dosing levels and schedules on drug efficacy and safety, which could ultimately mitigate the risk of adverse events, trial delays, and patient discontinuations. Most stakeholders expect that the usage of AI and innovative data analytics in drug development will continue to widen in the years ahead, with significant implications for the speed, efficiency, and costs of programs.


See Also :Towards A New World Order


Weekly Brief

loading
Top 10 Preeminent Cros – 2022
> <
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue

Read Also

Prophesying DNA Sequencing for 2023

Crucial Workflows of Next-Generation Sequencing

An Overview of Next-Generation Sequencing

The Role of AI in Accurate Medical Writing

Patrik Renblad to Join Cantargia as Chief Financial Officer

Overview of the Life Sciences BPO Market

Dr. Zamaneh Mikhak Joins TFF Pharmaceutical as the New Chief Medical Officer

The Significance of AI in Medical Writing

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/how-an-ai-boost-benefits-in-clinical-trials-nwid-365.html